| 1 |
human epidermal growth factor receptor 2
(7028 times)
|
Neoplasms
(3421 times)
|
ER (1423 times)
PR (1030 times)
HR (687 times)
|
1998 Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
|
| 2 |
human epidermal receptor 2
(65 times)
|
Neoplasms
(35 times)
|
EGFR (10 times)
ER (7 times)
OS (7 times)
|
2003 [Association between the survival time and high-expression of EGFR and HER-2 in breast cancer].
|
| 3 |
HER2/neu
(64 times)
|
Neoplasms
(39 times)
|
ER (14 times)
PR (12 times)
FISH (7 times)
|
1995 Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.
|
| 4 |
human EGFR2
(25 times)
|
Neoplasms
(9 times)
|
EGFR (20 times)
EGF (2 times)
PRL (2 times)
|
2005 Role of iron in inactivation of epidermal growth factor receptor after asbestos treatment of human lung and pleural target cells.
|
| 5 |
human EGF receptor 2
(24 times)
|
Neoplasms
(7 times)
|
ER (5 times)
EGFR (3 times)
PR (3 times)
|
2003 Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases.
|
| 6 |
human growth factor receptor 2
(10 times)
|
Neoplasms
(3 times)
|
AE (1 time)
BC (1 time)
DC (1 time)
|
2006 HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.
|
| 7 |
human ErbB2
(5 times)
|
Neoplasms
(4 times)
|
APC (2 times)
EGFR (1 time)
HIFU (1 time)
|
2005 Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
|
| 8 |
Her-2/neu protein
(3 times)
|
Neoplasms
(2 times)
|
ER (1 time)
FISH (1 time)
mHag (1 time)
|
2009 The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag).
|
| 9 |
HER2 over-expression
(3 times)
|
Radiology
(2 times)
|
TN (2 times)
BLBC (1 time)
BMI (1 time)
|
2016 Association Between Imaging Characteristics and Different Molecular Subtypes of Breast Cancer.
|
| 10 |
HER2-binding Z
(3 times)
|
Nuclear Medicine
(2 times)
|
PET (1 time)
|
2007 [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.
|
| 11 |
HER2-ECD
(3 times)
|
Allergy and Immunology
(1 time)
|
CLIA (1 time)
ECD (1 time)
ER (1 time)
|
2014 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
|
| 12 |
HER2-positive
(3 times)
|
Neoplasms
(2 times)
|
ADC (1 time)
BCS (1 time)
DFS (1 time)
|
2011 Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
|
| 13 |
HER2/neu receptor
(3 times)
|
General Surgery
(2 times)
|
HR (3 times)
CIs (1 time)
ER (1 time)
|
2011 Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.
|
| 14 |
hormone receptor 2
(3 times)
|
Neoplasms
(3 times)
|
ER (2 times)
CNB (1 time)
DFS (1 time)
|
2012 Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
|
| 15 |
human epidermal receptor protein-2
(3 times)
|
Pathology
(1 time)
|
ADC (1 time)
Dp (1 time)
ER (1 time)
|
2017 Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period.
|
| 16 |
anti-HER2 Affibody molecule Z
(2 times)
|
Biochemistry
(1 time)
|
MMA-NOTA (1 time)
|
2011 Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
|
| 17 |
anti-HER2 Z
(2 times)
|
Nuclear Medicine
(2 times)
|
CD (1 time)
ESI-MS (1 time)
maEES (1 time)
|
2008 Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
|
| 18 |
have ERBB2
(2 times)
|
Lung Neoplasms
(1 time)
|
cfDNA (1 time)
CNA (1 time)
CTCs (1 time)
|
2022 Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.
|
| 19 |
hEGF receptor-2
(2 times)
|
Neoplasms
(2 times)
|
---
|
2012 Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
|
| 20 |
HER2 amplification
(2 times)
|
Pathology
(1 time)
|
ER (1 time)
FISH (1 time)
PR (1 time)
|
2010 Triple-negative breast cancers: unique clinical presentations and outcomes.
|
| 21 |
HER2 and its Z
(2 times)
|
Nanomedicine
(1 time)
|
SPRi (1 time)
|
2015 Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.
|
| 22 |
HER2 protein
(2 times)
|
Pathology
(1 time)
|
HER2 ECD (1 time)
|
1996 Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu.
|
| 23 |
HER2-binding affibody molecule Z
(2 times)
|
Nuclear Medicine
(2 times)
|
---
|
2012 HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
|
| 24 |
HER2-enriched
(2 times)
|
Neoplasms
(2 times)
|
TN (2 times)
BC (1 time)
BCS (1 time)
|
2020 The influence of breast cancer subtype on survival after palliative radiation for osseous metastases.
|
| 25 |
HER2/neu/c-erbB2
(2 times)
|
Molecular Biology
(1 time)
|
APCs (1 time)
CHM (1 time)
CHP (1 time)
|
1994 Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides.
|
| 26 |
higher level expression of epidermal growth factor receptor 2
(2 times)
|
Neoplasms
(2 times)
|
ALDH1A1 (1 time)
CSC (1 time)
ER (1 time)
|
2014 ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis.
|
| 27 |
human c-ErbB2
(2 times)
|
Neoplasms
(1 time)
|
BC (1 time)
BCs (1 time)
|
2016 Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
|
| 28 |
human EGFR type 2 receptor
(2 times)
|
Neoplasms
(2 times)
|
EGFR (2 times)
TKIs (2 times)
ATP (1 time)
|
2014 Apoptosis-related molecular differences for response to tyrosin kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
|
| 29 |
human erb-b2 receptor tyrosine kinase 2
(2 times)
|
Pathology
(1 time)
|
CAR (1 time)
CNS (1 time)
MDA (1 time)
|
2020 Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX recurrence score using Magee Equations and Magee Decision Algorithm™.
|
| 30 |
human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2
(2 times)
|
Neoplasms
(1 time)
|
CI (1 time)
ECS (1 time)
GPCR (1 time)
|
2015 Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
|
| 31 |
anti-HER2 Affibody Z
(1 time)
|
Nuclear Medicine
(1 time)
|
PIB (1 time)
|
2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
|
| 32 |
anti-HER2 Affibody-PNA chimera, Z
(1 time)
|
Biochemistry
(1 time)
|
CD (1 time)
PNA (1 time)
SPR (1 time)
|
2015 Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.
|
| 33 |
Anti-HER2 Therapy in ERBB2
(1 time)
|
Precision Medicine
(1 time)
|
BC (1 time)
RD (1 time)
RPPA (1 time)
|
2019 Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer.
|
| 34 |
anti-human EGFR type 2
(1 time)
|
Drug Therapy
(1 time)
|
EGFR (1 time)
VEGF (1 time)
|
2007 EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
|
| 35 |
Anti-Human Epithelial Receptor Type 2
(1 time)
|
Neoplasms
(1 time)
|
GBM (1 time)
|
2007 Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
|
| 36 |
had advanced ERBB2
(1 time)
|
Neoplasms
(1 time)
|
PRC (1 time)
|
2019 Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.
|
| 37 |
had an ERBB2
(1 time)
|
Neoplasms
(1 time)
|
AC (1 time)
HBC (1 time)
|
2007 A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
|
| 38 |
had concurrent Erb-b2 receptor tyrosine kinase 2 gene
(1 time)
|
Neoplasms
(1 time)
|
CGP (1 time)
TMD (1 time)
|
2016 HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
|
| 39 |
had the same level of tumour accumulation as (125)I-PIB-Z
(1 time)
|
Nuclear Medicine
(1 time)
|
HPEM (1 time)
|
2008 Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
|
| 40 |
harboured similar gains, losses, amplifications of 9p23 and 17q12
(1 time)
|
Pathology
(1 time)
|
HUMARA (1 time)
|
2010 Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.
|
| 41 |
have frequently been linked to ERBB2
(1 time)
|
Molecular Biology
(1 time)
|
FISH (1 time)
|
2009 Aberrations of ERBB2 and TOP2A genes in breast cancer.
|
| 42 |
have identified patients eligible for studies by examining ERBB2
(1 time)
|
Neoplasms
(1 time)
|
ctDNA (1 time)
mCRC (1 time)
NGS (1 time)
|
2021 Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal Malignancies.
|
| 43 |
have resulted in the erb-b2 receptor tyrosine kinase 2 gene
(1 time)
|
Neoplasms
(1 time)
|
---
|
2019 Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
|
| 44 |
have shown that ERBB2
(1 time)
|
Neoplasms
(1 time)
|
cfDNA (1 time)
CNAs (1 time)
NGS (1 time)
|
2019 Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort.
|
| 45 |
HBEGF, ERBB2
(1 time)
|
Neoplasms
(1 time)
|
AREG (1 time)
BTC (1 time)
EPGN (1 time)
|
2014 Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
|
| 46 |
healthy controls showed that YAP and ERBB2
(1 time)
|
Heart Failure
(1 time)
|
hiPSC-CMs (1 time)
|
2021 Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy.
|
| 47 |
HER-2/neu oncogene
(1 time)
|
Pathology
(1 time)
|
topo IIalpha (1 time)
|
2006 Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
|
| 48 |
HER2 Affibody analogue, Ac-Cys-Z
(1 time)
|
Biochemistry
(1 time)
|
HSA (1 time)
PET (1 time)
SPECT (1 time)
|
2011 Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
|
| 49 |
HER2 and chromosome-17, as well for p185
(1 time)
|
Neoplasms
(1 time)
|
FISH (1 time)
|
2007 Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues.
|
| 50 |
HER2 FISH-ambiguous
(1 time)
|
General Surgery
(1 time)
|
FISH (1 time)
IHC (1 time)
|
2012 Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
|
| 51 |
HER2 growth factor receptor
(1 time)
|
Medicine
(1 time)
|
ER (1 time)
|
2020 Advances in the Molecular Taxonomy of Breast Cancer.
|
| 52 |
HER2 NT
(1 time)
|
Natural Science Disciplines
(1 time)
|
PDA (1 time)
|
2018 Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice.
|
| 53 |
HER2 oncogene or p185
(1 time)
|
Neoplasms
(1 time)
|
PDAC (1 time)
|
2004 Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
|
| 54 |
HER2 overexpressors. p185
(1 time)
|
Science
(1 time)
|
FAS (1 time)
RNAi (1 time)
|
2004 Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
|
| 55 |
HER2 PET
(1 time)
|
Nuclear Medicine
(1 time)
|
---
|
2008 Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.
|
| 56 |
HER2 receptor and Z
(1 time)
|
Allergy and Immunology
(1 time)
|
---
|
2008 Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
|
| 57 |
HER2 receptor more strongly, compared to Z
(1 time)
|
Biotechnology
(1 time)
|
---
|
2013 Affinity enhancement of HER2-binding Z(HER2:342) affibody via rational design approach: a molecular dynamics study.
|
| 58 |
HER2 receptor protein
(1 time)
|
General Surgery
(1 time)
|
DFS (1 time)
EGFR (1 time)
Ki67 (1 time)
|
2003 Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
|
| 59 |
HER2 targeting specificity, Z
(1 time)
|
Biochemistry
(1 time)
|
BNCs (1 time)
|
2010 Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells.
|
| 60 |
HER2 typically demonstrates the clear presence or lack of ERBB2
(1 time)
|
Pathology
(1 time)
|
ddPCR (1 time)
FISH (1 time)
IHC (1 time)
|
2020 Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups.
|
| 61 |
HER2+ with complete (100%) concordance with ERBB2
(1 time)
|
Neoplasms
(1 time)
|
CRGA (1 time)
GA (1 time)
IBC (1 time)
|
2015 Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
|
| 62 |
HER2-amplified
(1 time)
|
Biocompatible Materials
(1 time)
|
mPEG (1 time)
PLD (1 time)
|
2019 Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
|
| 63 |
HER2-aro
(1 time)
|
Neoplasms
(1 time)
|
AI (1 time)
ER (1 time)
|
2012 AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
|
| 64 |
HER2-binding surface of Z
(1 time)
|
Molecular Biology
(1 time)
|
PCA (1 time)
|
2010 Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
|
| 65 |
HER2-CAR T cells
(1 time)
|
Biotechnology
(1 time)
|
CAR (1 time)
HTS (1 time)
TME (1 time)
|
2022 3D hanging spheroid plate for high-throughput CAR T cell cytotoxicity assay.
|
| 66 |
Her2-coded p185
(1 time)
|
Neoplasms
(1 time)
|
ECD (1 time)
MUFA (1 time)
OA (1 time)
|
2006 Mediterranean diet, olive oil and cancer.
|
| 67 |
HER2-DIVMP
(1 time)
|
Chemistry
(1 time)
|
---
|
2012 Fluorescence study for selecting specific ligands toward HER2 receptor: an example of receptor fragment approach.
|
| 68 |
HER2-expressing cells of ((111)In-MMA-NODAGA-Cys(61))-Z
(1 time)
|
Biology
(1 time)
|
MMA-NODAGA (1 time)
|
2011 Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
|
| 69 |
HER2-expressing xenografts than the use of 125I-DABI-Z
(1 time)
|
Genetics, Medical
(1 time)
|
PIB (1 time)
|
2007 Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
|
| 70 |
HER2-expressing xenografts using 111In-benzyl-DOTA-Z
(1 time)
|
Genetics, Medical
(1 time)
|
pi (1 time)
|
2007 Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
|
| 71 |
HER2-expressing xenografts using radioiodinated Z
(1 time)
|
Nuclear Medicine
(1 time)
|
---
|
2006 Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
|
| 72 |
HER2-expressing xenografts using Z
(1 time)
|
Nuclear Medicine
(1 time)
|
---
|
2007 Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
|
| 73 |
HER2-low
(1 time)
|
Neoplasms
(1 time)
|
ADCs (1 time)
AGMT (1 time)
HER2-0 (1 time)
|
2021 Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
|
| 74 |
HER2-mab
(1 time)
|
Neoplasms
(1 time)
|
FISH (1 time)
GA (1 time)
GCN (1 time)
|
2012 p95HER2 truncated form in resected non-small cell lung cancer.
|
| 75 |
HER2-overexpressed xenografts (SKOV-3) by (186)Re-maGSG-Z
(1 time)
|
Nuclear Medicine
(1 time)
|
maGGG (1 time)
maGSG (1 time)
|
2009 (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.
|
| 76 |
HER2-overexpressing breast tumours co-expresses p95
(1 time)
|
Pathology
(1 time)
|
---
|
2012 Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
|
| 77 |
HER2-positive metastatic breast carcinoma with a coexisting ERBB2
(1 time)
|
Neoplasms
(1 time)
|
TTF-1 (1 time)
|
2015 Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
|
| 78 |
HER2-positive, ER-negative, PR-negative
(1 time)
|
Neoplasms
(1 time)
|
DFS (1 time)
ER (1 time)
FAC (1 time)
|
2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
|
| 79 |
HER2-specific Affibody molecule Z
(1 time)
|
Nuclear Medicine
(1 time)
|
---
|
2013 Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
|
| 80 |
HER2-specific Affibody tracer, (MMA-DOTA-Cys61)-Z
(1 time)
|
Molecular Biology
(1 time)
|
---
|
2010 Design of an optimized scaffold for affibody molecules.
|
| 81 |
HER2-targeted therapy for breast and gastric patients with ERBB2
(1 time)
|
Neoplasms
(1 time)
|
---
|
2018 Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
|
| 82 |
HER2-targeting agents Z
(1 time)
|
Nuclear Medicine
(1 time)
|
---
|
2008 Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.
|
| 83 |
HER2/c-erbB-2
(1 time)
|
Pathology
(1 time)
|
dPCR (1 time)
FISH (1 time)
IHC (1 time)
|
2003 Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
|
| 84 |
her2/neu gene
(1 time)
|
Antineoplastic Agents
(1 time)
|
---
|
2012 A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers.
|
| 85 |
HER2/neu gene encodes a 185 kDa transmembrane receptor
(1 time)
|
Drug Therapy
(1 time)
|
---
|
2003 Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.
|
| 86 |
HER2CA
(1 time)
|
Natural Science Disciplines
(1 time)
|
ARE (1 time)
DN-NRF2 (1 time)
|
2014 HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction.
|
| 87 |
Herceptin-2
(1 time)
|
Biology
(1 time)
|
CA125 (1 time)
CEA (1 time)
ECBs (1 time)
|
2020 Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing.
|
| 88 |
heterodimer with other ErbB family members, such as ErbB2
(1 time)
|
Molecular Biology
(1 time)
|
EGF (1 time)
EGFR (1 time)
HRGbeta1 (1 time)
|
2011 Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
|
| 89 |
Heterodimers of the ligand-binding-deficient ERBB2
(1 time)
|
Science
(1 time)
|
ECD (1 time)
|
2012 Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
|
| 90 |
heterogeneous ERBB2
(1 time)
|
Molecular Biology
(1 time)
|
FISH (1 time)
qPCR (1 time)
|
2013 Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma.
|
| 91 |
high ERBB2
(1 time)
|
Neoplasms
(1 time)
|
HER2Mab (1 time)
|
2013 ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
|
| 92 |
high frequency of activating extracellular domain ERBB2
(1 time)
|
Neoplasms
(1 time)
|
MPUC (1 time)
NGS (1 time)
non-MPUC (1 time)
|
2013 A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
|
| 93 |
high levels of erbB2
(1 time)
|
Neoplasms
(1 time)
|
---
|
2016 Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.
|
| 94 |
high melting temperature (T(m)), both in HP1:HP2 and in Z
(1 time)
|
Biochemistry
(1 time)
|
CD (1 time)
PNA (1 time)
SPR (1 time)
|
2015 Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.
|
| 95 |
high-grade ERBB2
(1 time)
|
Neoplasms
(1 time)
|
CI (1 time)
|
2019 ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab.
|
| 96 |
higher for (124)I-PIB-Z
(1 time)
|
Nuclear Medicine
(1 time)
|
PIB (1 time)
|
2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
|
| 97 |
higher frequency of focal BRAF and ERBB2
(1 time)
|
Adolescent
(1 time)
|
ACRC (1 time)
cfDNA (1 time)
|
2020 Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer.
|
| 98 |
higher rates in patients with epidermal growth factor receptor 2
(1 time)
|
Neoplasms
(1 time)
|
BC (1 time)
BMs (1 time)
MBC (1 time)
|
2015 Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases.
|
| 99 |
higher sensitivity to predict ERBB2
(1 time)
|
Neoplasms
(1 time)
|
DFS (1 time)
ECD (1 time)
QIF (1 time)
|
2015 Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
|
| 100 |
higher than that of (124)I-PIB-Z
(1 time)
|
Nuclear Medicine
(1 time)
|
PIB (1 time)
|
2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
|
A Search Service for Abbreviation / Long Form